NAIMA method
•Download as PPT, PDF•
2 likes•759 views
The document describes a new method called NAIMA-MA (Nucleic Acid Sequence-Based Amplification integrated Multiplex Amplification) that allows for fast, high-throughput and quantitative detection of genetically modified organisms (GMOs). NAIMA-MA uses isothermal amplification to simultaneously amplify multiple DNA targets in a sample in under 25 minutes. The amplified products can then be directly detected on microarrays, providing identification and quantification of GMOs in one step with high sensitivity down to less than 20 DNA copies. The method shows potential for improving current GMO detection techniques by offering higher throughput, lower costs, and simplified workflow compared to quantitative PCR (qPCR).
Report
Share
Report
Share
![APPLICATION OF NAIMA-MA FOR FAST HIGH THROUGHPUT AND QUANTITATIVE GMO DETECTION Dany Morisset , David Dobnik, Tina Likar and Kristina Gruden Department of Biotechnology and Systems Biology National Institute of Biology Ljubljana, Slovenia [email_address]](https://image.slidesharecdn.com/danydalianv2-1260271038817-phpapp01/85/NAIMA-method-1-320.jpg)
![[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Nucleic Acid Sequence-Based Amplification (NASBA)](data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7)
Recommended
Unveiling the Potential of your AAV Gene Therapy: Orthogonal methods to under...
Watch the presentation of this webinar here: https://bit.ly/3pCCjPF
Ensure your Adeno-Associated Virus (AAV) is safe throughout its entire drug development journey. Learn methods that will help you speed to clinic, potentially treating diseases sooner and with greater effectiveness.
The potential of gene therapies to cure previously untreatable diseases has spurred the development of novel drugs, including those based on Adeno-Associated Virus (AAV). As with all biopharmaceuticals, it is important to identify and monitor the critical quality attributes (CQAs) of these products to ensure their safety and efficacy.
In this webinar, we will present a range of orthogonal methods to understand and define the CQAs of AAV products. These include assays for the confirmation of capsid protein identity and quantity, as well as the characterization of important product-related impurities, such as aggregates. Together these methods represent a comprehensive analytical testing package to support the characterization and lot release of AAV products.
In this webinar, you will learn:
• How to identify and monitor the critical quality attributes (CQAs) of your AAV therapy
• What assays to utilize to confirm capsid protein identity and quantity
• Why you need look to product characterization to identify and remove important product-related impurities
See the Whole Picture: Using SV-AUC for Empty/Full AAV Capsid Analysis
Watch this webinar here: https://bit.ly/31ZZM3n
Join this webinar for key insights on using the SV-AUC assay for empty/full analysis of your AAV viral vector. We’ll cover the technical requirements for this assay, data interpretation, and finally how this assay fits into the larger picture of AAV characterization.
Recombinant adeno-associated viruses (AAV) are widely used as gene transfer vectors. However, AAV production generates mixed populations of viral capsids containing either complete viral vector genome (full capsids); partially filled, and those lacking the viral genome (empty capsids). Sedimentation Velocity Analytical Ultracentrifugation (SV-AUC) offers a robust, accurate, and consistent method for characterizing empty/full AAV capsid composition. In this webinar we will review the key technical requirements for performing an AUC assay as well as analysis and data interpretation of the results generated.
In this webinar, you will learn:
• Regulatory expectations for empty/full analysis
• Key technical requirements for running an AUC assay and how to interpret the data from the results generated
• How the AUC assay fits into the larger picture of AAV characterization
Releasing Your AAV Therapy with Confidence: Regulatory Considerations and Key...
Watch the presentation of this webinar here: https://bit.ly/3icKkbZ
Ensuring the safety and quality of your AAV vector is of the utmost importance. Join this webinar for a high-level overview of the regulatory requirements for AAV testing throughout the manufacturing process, as well as a more detailed look at rcAAV and infectious titer assays.
Adeno-associated virus (AAV) vectors possess a number of advantages for use in human therapy including: high titer preparations, low immunogenicity, capacity to infect a wide range of cell types, and replication deficiency. Even with these advantages, there are biosafety concerns to consider when using AAV vectors.
This webinar will discuss key regulatory considerations across the manufacturing process, from the helper/packaging plasmids through to lot release testing. We will highlight critical assays that are required and delve into specifics on replication competent AAV testing and infectious titer determination by TCID50.
In this webinar, you will learn:
• Critical biosafety considerations for AAV vectors based on the latest regulatory guidance
• How replication competent AAV testing fits into your bulk and final release testing package
• The benefits of routine and platform assays over custom assay development
Presented by:
Steven McDade, Senior Technical Specialist, Field Technology Management
Alfonso Lavorgna, Ph.D., Operations Manager, Virology Services
Setting up for successful lot release testing by Edmund Ang
Is your lot release testing strategy ready for global commercialization?
In this webinar, you will learn:
• CMC testing requirements with CHO production platform for global commercialization
• Lot release testing of product intermediates and final product
• Product-specific qualification study
• Alternative rapid testing methods to advance lot release testing
CHO cells continue to serve as a key cell substrate for the manufacturing of recombinant proteins that span beyond therapeutic monoclonal antibodies and including subunit vaccines.
In this presentation, we will cover the CMC testing requirements with CHO production platform for global commercialization, Lot release testing of product intermediates and final product, product-specific qualification study and highlight the application of new testing methods and the benefits they bring to advance Lot Release Testing.
Breaking the Status Quo: Using Mass Spectrometry to detect Host Cell Proteins
Watch the presentation of this webinar here: https://bit.ly/3b3Tbcd
Measurement of host cell proteins is vital to ensuring a biotherapy's purity and a patient's safety. Biotherapies treat diseases with products produced by living organisms, as a result, host cell components must be characterized and controlled. We'll review new methods within product characterization for detection.
Trace amounts of host cell proteins can be present after the production and purification of any biopharmaceutical. Detection of these species requires highly specific techniques to accurately quantify even low levels of contamination. Host cell protein impurities, present at PPM-levels in biotherapies, are a major immunogenicity risk because they can elicit an unpredictable immune response in patients. Their complex and diverse nature makes them challenging to detect or monitor. With acceptance criteria for host residual DNA usually set at a very low level (often =1.0 pg of DNA per mg of drug substance), effective removal techniques and sensitive methods of detection are critical.
Antibody-based techniques, like the enzyme-linked immunosorbent assay (ELISA), have been used to assess the HCP load of biotherapeutics before and after process changes. However, these techniques do not necessarily detect qualitative changes in the HCP population. In this webinar, we will discuss how mass spectrometry (MS)-based approaches coupled with ELISA methods help detect qualitative and quantitative differences in HCP populations.
In this webinar, you will learn:
• Comprehensive HCP ID and semi-quantitation
• HC agnostic process
• Creation of process specific database
• Differential clearance of specific HCPs throughout purification steps
• Monitoring of problematic species e.g. immunogenic (PLBL2), lipases and proteases
• Explanation about why 90% of BLAs filed included this HCP MS data
An Integrated Approach to Ensure Viral Vector and Gene Therapy Commercial Rea...
Come learn more about our integrated approach to ensure viral vector and gene therapy commercial readiness. We will discuss topics relating to process development for viral vector manufacturing, biosafety testing and commercial readiness.
Significant progress has been made for the use of viral vectors for gene therapy. Promising clinical trial results as well as recent FDA approval for CAR-T cell therapy to treat certain children and young adults with B-cell lymphoblastic leukemia have signaled advancements in the field. This marks a historic action, providing opportunities for new viral vector technologies to transform medicine and the way patients are treated and even cured. The need for process development for viral vector manufacturing to improve yield to meet patient demand, biosafety testing for product characterization, potency and safety and commercial readiness to accelerate therapy to-market are critically important. Here, we emphasis an integrated approach that allows our customers solutions to ensure viral vector and gene therapy commercial readiness to meet the growing market need.
In this webinar, you will learn:
● Process development advances for production scale-up of viral vectors for gene therapy
● Methods specific for viral gene therapy product characterization, purity, potency, safety and release testing
● Commercial readiness through our US and UK Centers of Excellence for viral product manufacturing
Biosafety in Gene Therapy: Applying the latest regulatory guidance for RCL te...
Watch the presentation of this webinar here: https://bit.ly/33WUiqE
Ensuring the safety and quality of your lentiviral vector is of the utmost importance. Attend this webinar to learn about testing strategies to monitor replication competent lentivirus. You will also hear about recent changes in regulatory guidance with regards to sample types and volumes tested.
The use of lentivirus vectors to produce groundbreaking gene therapies is on the rise. Ensuring the biosafety and quality of these vectors is achieved through a multi-tiered testing approach.
For lentivirus-based therapies, generation of replication competent particles is a potential risk. While improvements in design and manufacturing have decreased the probability of producing replication competent viruses, regulatory agencies provide guidelines to test for their presence at multiple stages in production. This webinar reviews the strategies for monitoring replication competent lentiviruses. We describe current methods and address: Sample types, testing volumes, and expected results.
In this webinar, you will learn about:
• The latest FDA regulatory guidelines on replication competent lentivirus (RCL) testing
• Methods used to monitor RCL
• Considerations on sample type and volume requirements
Recommended
Unveiling the Potential of your AAV Gene Therapy: Orthogonal methods to under...
Watch the presentation of this webinar here: https://bit.ly/3pCCjPF
Ensure your Adeno-Associated Virus (AAV) is safe throughout its entire drug development journey. Learn methods that will help you speed to clinic, potentially treating diseases sooner and with greater effectiveness.
The potential of gene therapies to cure previously untreatable diseases has spurred the development of novel drugs, including those based on Adeno-Associated Virus (AAV). As with all biopharmaceuticals, it is important to identify and monitor the critical quality attributes (CQAs) of these products to ensure their safety and efficacy.
In this webinar, we will present a range of orthogonal methods to understand and define the CQAs of AAV products. These include assays for the confirmation of capsid protein identity and quantity, as well as the characterization of important product-related impurities, such as aggregates. Together these methods represent a comprehensive analytical testing package to support the characterization and lot release of AAV products.
In this webinar, you will learn:
• How to identify and monitor the critical quality attributes (CQAs) of your AAV therapy
• What assays to utilize to confirm capsid protein identity and quantity
• Why you need look to product characterization to identify and remove important product-related impurities
See the Whole Picture: Using SV-AUC for Empty/Full AAV Capsid Analysis
Watch this webinar here: https://bit.ly/31ZZM3n
Join this webinar for key insights on using the SV-AUC assay for empty/full analysis of your AAV viral vector. We’ll cover the technical requirements for this assay, data interpretation, and finally how this assay fits into the larger picture of AAV characterization.
Recombinant adeno-associated viruses (AAV) are widely used as gene transfer vectors. However, AAV production generates mixed populations of viral capsids containing either complete viral vector genome (full capsids); partially filled, and those lacking the viral genome (empty capsids). Sedimentation Velocity Analytical Ultracentrifugation (SV-AUC) offers a robust, accurate, and consistent method for characterizing empty/full AAV capsid composition. In this webinar we will review the key technical requirements for performing an AUC assay as well as analysis and data interpretation of the results generated.
In this webinar, you will learn:
• Regulatory expectations for empty/full analysis
• Key technical requirements for running an AUC assay and how to interpret the data from the results generated
• How the AUC assay fits into the larger picture of AAV characterization
Releasing Your AAV Therapy with Confidence: Regulatory Considerations and Key...
Watch the presentation of this webinar here: https://bit.ly/3icKkbZ
Ensuring the safety and quality of your AAV vector is of the utmost importance. Join this webinar for a high-level overview of the regulatory requirements for AAV testing throughout the manufacturing process, as well as a more detailed look at rcAAV and infectious titer assays.
Adeno-associated virus (AAV) vectors possess a number of advantages for use in human therapy including: high titer preparations, low immunogenicity, capacity to infect a wide range of cell types, and replication deficiency. Even with these advantages, there are biosafety concerns to consider when using AAV vectors.
This webinar will discuss key regulatory considerations across the manufacturing process, from the helper/packaging plasmids through to lot release testing. We will highlight critical assays that are required and delve into specifics on replication competent AAV testing and infectious titer determination by TCID50.
In this webinar, you will learn:
• Critical biosafety considerations for AAV vectors based on the latest regulatory guidance
• How replication competent AAV testing fits into your bulk and final release testing package
• The benefits of routine and platform assays over custom assay development
Presented by:
Steven McDade, Senior Technical Specialist, Field Technology Management
Alfonso Lavorgna, Ph.D., Operations Manager, Virology Services
Setting up for successful lot release testing by Edmund Ang
Is your lot release testing strategy ready for global commercialization?
In this webinar, you will learn:
• CMC testing requirements with CHO production platform for global commercialization
• Lot release testing of product intermediates and final product
• Product-specific qualification study
• Alternative rapid testing methods to advance lot release testing
CHO cells continue to serve as a key cell substrate for the manufacturing of recombinant proteins that span beyond therapeutic monoclonal antibodies and including subunit vaccines.
In this presentation, we will cover the CMC testing requirements with CHO production platform for global commercialization, Lot release testing of product intermediates and final product, product-specific qualification study and highlight the application of new testing methods and the benefits they bring to advance Lot Release Testing.
Breaking the Status Quo: Using Mass Spectrometry to detect Host Cell Proteins
Watch the presentation of this webinar here: https://bit.ly/3b3Tbcd
Measurement of host cell proteins is vital to ensuring a biotherapy's purity and a patient's safety. Biotherapies treat diseases with products produced by living organisms, as a result, host cell components must be characterized and controlled. We'll review new methods within product characterization for detection.
Trace amounts of host cell proteins can be present after the production and purification of any biopharmaceutical. Detection of these species requires highly specific techniques to accurately quantify even low levels of contamination. Host cell protein impurities, present at PPM-levels in biotherapies, are a major immunogenicity risk because they can elicit an unpredictable immune response in patients. Their complex and diverse nature makes them challenging to detect or monitor. With acceptance criteria for host residual DNA usually set at a very low level (often =1.0 pg of DNA per mg of drug substance), effective removal techniques and sensitive methods of detection are critical.
Antibody-based techniques, like the enzyme-linked immunosorbent assay (ELISA), have been used to assess the HCP load of biotherapeutics before and after process changes. However, these techniques do not necessarily detect qualitative changes in the HCP population. In this webinar, we will discuss how mass spectrometry (MS)-based approaches coupled with ELISA methods help detect qualitative and quantitative differences in HCP populations.
In this webinar, you will learn:
• Comprehensive HCP ID and semi-quantitation
• HC agnostic process
• Creation of process specific database
• Differential clearance of specific HCPs throughout purification steps
• Monitoring of problematic species e.g. immunogenic (PLBL2), lipases and proteases
• Explanation about why 90% of BLAs filed included this HCP MS data
An Integrated Approach to Ensure Viral Vector and Gene Therapy Commercial Rea...
Come learn more about our integrated approach to ensure viral vector and gene therapy commercial readiness. We will discuss topics relating to process development for viral vector manufacturing, biosafety testing and commercial readiness.
Significant progress has been made for the use of viral vectors for gene therapy. Promising clinical trial results as well as recent FDA approval for CAR-T cell therapy to treat certain children and young adults with B-cell lymphoblastic leukemia have signaled advancements in the field. This marks a historic action, providing opportunities for new viral vector technologies to transform medicine and the way patients are treated and even cured. The need for process development for viral vector manufacturing to improve yield to meet patient demand, biosafety testing for product characterization, potency and safety and commercial readiness to accelerate therapy to-market are critically important. Here, we emphasis an integrated approach that allows our customers solutions to ensure viral vector and gene therapy commercial readiness to meet the growing market need.
In this webinar, you will learn:
● Process development advances for production scale-up of viral vectors for gene therapy
● Methods specific for viral gene therapy product characterization, purity, potency, safety and release testing
● Commercial readiness through our US and UK Centers of Excellence for viral product manufacturing
Biosafety in Gene Therapy: Applying the latest regulatory guidance for RCL te...
Watch the presentation of this webinar here: https://bit.ly/33WUiqE
Ensuring the safety and quality of your lentiviral vector is of the utmost importance. Attend this webinar to learn about testing strategies to monitor replication competent lentivirus. You will also hear about recent changes in regulatory guidance with regards to sample types and volumes tested.
The use of lentivirus vectors to produce groundbreaking gene therapies is on the rise. Ensuring the biosafety and quality of these vectors is achieved through a multi-tiered testing approach.
For lentivirus-based therapies, generation of replication competent particles is a potential risk. While improvements in design and manufacturing have decreased the probability of producing replication competent viruses, regulatory agencies provide guidelines to test for their presence at multiple stages in production. This webinar reviews the strategies for monitoring replication competent lentiviruses. We describe current methods and address: Sample types, testing volumes, and expected results.
In this webinar, you will learn about:
• The latest FDA regulatory guidelines on replication competent lentivirus (RCL) testing
• Methods used to monitor RCL
• Considerations on sample type and volume requirements
Promises and Challenges of Manufacturing and Testing Viral Producer Cell Lines
To date, manufacturing of lentivirus (LV) vectors for gene therapy commonly relies on transient transfection of adherent HEK293 cells. This method is costly, time-consuming, difficult to scale-up and poorly reproducible, rendering large-scale applicability to fulfill increasing demand of LV in clinical pipelines cumbersome. The use of suspension-adapted transient producer cell lines for LV production has overcome some of these challenges. Furthermore, successful creation of stable producer cell lines would allow creation of master and working cell banks easily amenable to commercial production. The ideal producer cell lines should demonstrate stability in growth and gene expression, and be easily adaptable to chemically defined culture conditions and optimized for high-titer virus production. The availability of more robust producer cell lines thus represents an important scalable first step towards manufacturing processes that are conducive to large-scale production. Ultimately, these producer cell lines must be screened to satisfy various biosafety and regulatory implications.
In this webinar, you will learn:
• Process development for transient and stable producer cell lines
• Screening of cellular gene targets via CRISPR to improve LV production from producer cell lines
• cGMP and Regulatory readiness: Cell line characterization and release testing through BioReliance® global service offering
Does your cell line have a secret? Avoid surprises with characterization
Watch the recording of this webinar here: https://bit.ly/2Y05bV4
The first step to avoiding an unpleasant and costly contamination event is characterization of your cell banks.
Regardless of the biotech product, careful characterization of the cell banks used in its production is the first step in mitigating the risk of a contamination event. In fact, cell line characterization is an important component of the overall viral safety strategy for the product. We will describe the testing necessary to ensure cell banks are free from infectious and other adverse agents and that meets current regulatory expectations. Different levels of testing are performed for master, working, and end of production cell banks, and the differences in testing for each of these types of banks will be discussed.
In this webinar, you will learn:
• The types of tests that are needed to fully characterize your cell banks
• The best tests to use for your particular cell line
• Reasons why a viral contaminant may be missed
Rapid Methodologies for Biosafety Testing of Biologic Therapeutics
Learn about existing and emerging methods to accelerate biosafety testing of biologic therapies.
Speed to market for biologic therapeutics is ever more critical. However, the critical safety tests for these molecules, for example screening for adventitious agents such as viral contaminants, can be time consuming as well as challenging and laborious. Join us for this webinar as we explore how rapid methodologies are being used to not only accelerate this process, but also enhance quality by reducing testing complexity. Existing technologies as well as emerging trends will be discussed, along with the implications these may have on the regulatory landscape.
In this webinar you will learn:
● Which existing and emerging technologies are having now, and will have in the future, an impact on biosaftey testing.
● The benefits as well as risks of employing rapid methods for biosafety screening.
● How the regulatory agencies are reacting to rapid testing methods as alternatives to existing methods.
New technology and workflow for integrated collection, stabilization and puri...
Research into non-invasive prenatal testing (NIPT) and circulating tumor DNA (ctDNA) testing based on circulating cell-free DNA (ccfDNA) is rapidly expanding. However, detection and quantification of ccfDNA is compromised by the release of genomic DNA (gDNA) from lymphocytes due to mechanical lysis or apoptosis during blood collection, storage and transport. PreAnalytiX has developed the PAXgene Blood ccfDNA System, consisting of the PAXgene Blood ccfDNA Tube, a plastic blood collection tube with a unique, non-crosslinking chemistry that preserves extracellular levels of ccfDNA and prevents the release of intracellular DNA from cells into the plasma, and the QIAsymphonyPAXgene Blood ccfDNA Kit for automated ccfDNA extraction from up to 5 ml of plasma. In this slidedeck, this new technology development is presented in comparison to other existing technologies.
Viral Risk Mitigation Strategies: Key Considerations in the Prevention and De...
Regulatory guidelines have defined industry best practices around adventitious virus contamination and risk mitigation in terms of patient safety.
Today, the industry is taking a closer look at minimizing the business risk associated with viral contamination and is taking a more directed view of risk mitigation. This approach includes virus prevention and detection, in addition to removal.
From cell culture seed train to final fill vial, this presentation will describe:
-Potential risks associated with different areas of biotech processes
-What can be done to minimize adventitious virus risk in those areas.
The overarching strategy of risk mitigation will include evaluation of raw materials, modified expression systems, environmental controls, upstream and downstream processing, as well as testing and regulatory considerations.
Addressing the Pre-PCR Analytical Variability of FFPE Samples
Despite technical advances, assessing the accuracy of pre-PCR steps, which include DNA extraction from formalin-fixed paraffin-embedded (FFPE) tissues, DNA quantitation and DNA quality control, remain a key challenge in external quality assurance.
In the webinar we will discuss the latest results from recent studies and look at ways that the accuracy of pre-PCR workflows can be improved.
TestGene catalogue
Main file> http://www.slideshare.net/rustradeESP/testgene
TestGene develops and manufactures kits for molecular genetics. Products are intended for use in research, practical medicine, and in the fields of molecular biology. The focus area – non-invasive genetic testing in obstetrics and oncology. The company has its own production laboratory with the necessary equipment for manufacturing and quality assurance of kits based on "real time PCR".
Platform Technologies to Accelerate Novel Vaccine Development and Manufacturing
Watch the presentation of this webinar here: https://bit.ly/3jmLYHu
State-of-the-art vaccine technologies are transforming vaccine development, and solutions for fast and reliable production are needed.
The vaccine industry has undergone a revolution in technology resulting in a variety of novel therapeutic platforms that accelerate development and significantly reduce the duration for process optimization and scale-up. However, challenges in maintaining efficacy and improving process robustness remain. In this presentation, we present a comparison of these novel technologies, discuss key considerations for manufacturing and share selected case studies for platforms such as virus-like-particles, viral vectors, plasmid DNA, and mRNA platform.
In this webinar, you will learn:
• Benefits of platform technologies in vaccine development
• Key considerations when deciding between platforms
• Vaccine pipeline analysis and selected case studies
Presented by:
David Loong, Ph.D, Senior Consultant, Novel Modalities Asia Pacific, Bioprocessing Strategy
Josephine Cheng, Senior Consultant, Core Modalities Asia Pacific, Bioprocessing Strategy
Gene Xpert
This is a presentation giving an overview of the GeneXpert DX system for detection of MTB. The assay described in this presentation is the MTB/RIF test.
New Technology and Workflow for Integrated Collection, Stabilization and Puri...
Research into non-invasive prenatal testing (NIPT) and circulating tumor DNA (ctDNA) testing based on circulating cell-free DNA (ccfDNA) is rapidly expanding. However, detection and quantification of ccfDNA is compromised by the release of genomic DNA (gDNA) from lymphocytes due to mechanical lysis or apoptosis during blood collection, storage and transport. PreAnalytiX has developed the PAXgene® Blood ccfDNA System, consisting of the PAXgene Blood ccfDNA Tube, a plastic blood collection tube with a unique, non-crosslinking chemistry that preserves extracellular levels of ccfDNA and prevents the release of intracellular DNA from cells into the plasma, and the QIAsymphony® PAXgene Blood ccfDNA Kit for automated ccfDNA extraction from up to 5 ml of plasma. In this webinar, this new technology development is presented in comparison to other existing technologies.
Use of rapid quality control test methods as alternatives to traditional meth...
Abstract:
As the market for advanced therapy medicinal products (ATMP) matures the complexities of these molecules are evident and challenging when routine standard quality control (QC) testing is applied. Short shelf life from the point of manufacture to administration to the patient results in relatively low volumes for small scale clinical trials or small patient populations. Within a limited time period and with this low product volume, it is necessary to complete required regulatory QC testing, be that for early or late phase clinical trials, or for licensed drug product in a reduced timescale. So, the challenges with QC testing of cell and gene therapies using traditional test methods is time to results, due to short shelf-life, and availability of sufficient sample, due to low production volumes. Over the past years the application of rapid testing of short-life cell and gene therapies that may also help conserve limited product availability have been utilised. Regulatory expectations for using rapid test methods in place of classical or compendial test methods have been defined and this presentation will provide examples and data from our own experience of a range of alternate methods for application to ATMP products.
To assess the effect of formalin on genomic DNA and assay performance for som...
What is the impact of assay failure in your laboratory and how do you monitor for it?
Application of Companion Diagnostics - driving better treatment for cancer patients
AAV production protocol:packaging,concentration and purification-gene medi
AAV production protocol for AAV vector construction, AAV packaging and AAV purification.
Massively parallel sequencing in forensic genetics
"Massively parallel sequencing in forensic genetics
Dr. Walther Parson
assoc. Prof. Institute of Legal Medicine, Innsbruck, Austria
adj. Prof. Penn State University, PA, USA"
Rapid and real-time diagnosis of Laem-Singh virus using a portable Real-Amp T...
The most prominent of growth-retarded in black tiger shrimp (Penaeus monodon) is associated with an infection of Laem-Singh virus (LSNV) that has been involved the reduction of annual production volume. To more accurately, rapidly and easily determine its effect on shrimp industries for further control disease, a portable Real-Amp Turbidimeter with real-time detection method was evaluated for LSNV detection.The device exploited the turbidity that produced by-product of magnesium pyrophosphate and displayed turbidity values in real-time on the provided software screen. The results of quantitative can be accomplished by reaction time measuring. The sensitivity of a turbidity detection was comparable to that of the nested RT-PCR, while it was 1000-time more sensitive than RT-PCR. With the use of a portable Real-Amp Turbidimeter. The application of RT-LAMP using a portable Real-Amp Turbidimeter offers a simple and rapid detection platform for LSNV detection in the field assessment. So, This 's awesome technic not only for detection of LSNV but also for many pathogen.
More Related Content
What's hot
Promises and Challenges of Manufacturing and Testing Viral Producer Cell Lines
To date, manufacturing of lentivirus (LV) vectors for gene therapy commonly relies on transient transfection of adherent HEK293 cells. This method is costly, time-consuming, difficult to scale-up and poorly reproducible, rendering large-scale applicability to fulfill increasing demand of LV in clinical pipelines cumbersome. The use of suspension-adapted transient producer cell lines for LV production has overcome some of these challenges. Furthermore, successful creation of stable producer cell lines would allow creation of master and working cell banks easily amenable to commercial production. The ideal producer cell lines should demonstrate stability in growth and gene expression, and be easily adaptable to chemically defined culture conditions and optimized for high-titer virus production. The availability of more robust producer cell lines thus represents an important scalable first step towards manufacturing processes that are conducive to large-scale production. Ultimately, these producer cell lines must be screened to satisfy various biosafety and regulatory implications.
In this webinar, you will learn:
• Process development for transient and stable producer cell lines
• Screening of cellular gene targets via CRISPR to improve LV production from producer cell lines
• cGMP and Regulatory readiness: Cell line characterization and release testing through BioReliance® global service offering
Does your cell line have a secret? Avoid surprises with characterization
Watch the recording of this webinar here: https://bit.ly/2Y05bV4
The first step to avoiding an unpleasant and costly contamination event is characterization of your cell banks.
Regardless of the biotech product, careful characterization of the cell banks used in its production is the first step in mitigating the risk of a contamination event. In fact, cell line characterization is an important component of the overall viral safety strategy for the product. We will describe the testing necessary to ensure cell banks are free from infectious and other adverse agents and that meets current regulatory expectations. Different levels of testing are performed for master, working, and end of production cell banks, and the differences in testing for each of these types of banks will be discussed.
In this webinar, you will learn:
• The types of tests that are needed to fully characterize your cell banks
• The best tests to use for your particular cell line
• Reasons why a viral contaminant may be missed
Rapid Methodologies for Biosafety Testing of Biologic Therapeutics
Learn about existing and emerging methods to accelerate biosafety testing of biologic therapies.
Speed to market for biologic therapeutics is ever more critical. However, the critical safety tests for these molecules, for example screening for adventitious agents such as viral contaminants, can be time consuming as well as challenging and laborious. Join us for this webinar as we explore how rapid methodologies are being used to not only accelerate this process, but also enhance quality by reducing testing complexity. Existing technologies as well as emerging trends will be discussed, along with the implications these may have on the regulatory landscape.
In this webinar you will learn:
● Which existing and emerging technologies are having now, and will have in the future, an impact on biosaftey testing.
● The benefits as well as risks of employing rapid methods for biosafety screening.
● How the regulatory agencies are reacting to rapid testing methods as alternatives to existing methods.
New technology and workflow for integrated collection, stabilization and puri...
Research into non-invasive prenatal testing (NIPT) and circulating tumor DNA (ctDNA) testing based on circulating cell-free DNA (ccfDNA) is rapidly expanding. However, detection and quantification of ccfDNA is compromised by the release of genomic DNA (gDNA) from lymphocytes due to mechanical lysis or apoptosis during blood collection, storage and transport. PreAnalytiX has developed the PAXgene Blood ccfDNA System, consisting of the PAXgene Blood ccfDNA Tube, a plastic blood collection tube with a unique, non-crosslinking chemistry that preserves extracellular levels of ccfDNA and prevents the release of intracellular DNA from cells into the plasma, and the QIAsymphonyPAXgene Blood ccfDNA Kit for automated ccfDNA extraction from up to 5 ml of plasma. In this slidedeck, this new technology development is presented in comparison to other existing technologies.
Viral Risk Mitigation Strategies: Key Considerations in the Prevention and De...
Regulatory guidelines have defined industry best practices around adventitious virus contamination and risk mitigation in terms of patient safety.
Today, the industry is taking a closer look at minimizing the business risk associated with viral contamination and is taking a more directed view of risk mitigation. This approach includes virus prevention and detection, in addition to removal.
From cell culture seed train to final fill vial, this presentation will describe:
-Potential risks associated with different areas of biotech processes
-What can be done to minimize adventitious virus risk in those areas.
The overarching strategy of risk mitigation will include evaluation of raw materials, modified expression systems, environmental controls, upstream and downstream processing, as well as testing and regulatory considerations.
Addressing the Pre-PCR Analytical Variability of FFPE Samples
Despite technical advances, assessing the accuracy of pre-PCR steps, which include DNA extraction from formalin-fixed paraffin-embedded (FFPE) tissues, DNA quantitation and DNA quality control, remain a key challenge in external quality assurance.
In the webinar we will discuss the latest results from recent studies and look at ways that the accuracy of pre-PCR workflows can be improved.
TestGene catalogue
Main file> http://www.slideshare.net/rustradeESP/testgene
TestGene develops and manufactures kits for molecular genetics. Products are intended for use in research, practical medicine, and in the fields of molecular biology. The focus area – non-invasive genetic testing in obstetrics and oncology. The company has its own production laboratory with the necessary equipment for manufacturing and quality assurance of kits based on "real time PCR".
Platform Technologies to Accelerate Novel Vaccine Development and Manufacturing
Watch the presentation of this webinar here: https://bit.ly/3jmLYHu
State-of-the-art vaccine technologies are transforming vaccine development, and solutions for fast and reliable production are needed.
The vaccine industry has undergone a revolution in technology resulting in a variety of novel therapeutic platforms that accelerate development and significantly reduce the duration for process optimization and scale-up. However, challenges in maintaining efficacy and improving process robustness remain. In this presentation, we present a comparison of these novel technologies, discuss key considerations for manufacturing and share selected case studies for platforms such as virus-like-particles, viral vectors, plasmid DNA, and mRNA platform.
In this webinar, you will learn:
• Benefits of platform technologies in vaccine development
• Key considerations when deciding between platforms
• Vaccine pipeline analysis and selected case studies
Presented by:
David Loong, Ph.D, Senior Consultant, Novel Modalities Asia Pacific, Bioprocessing Strategy
Josephine Cheng, Senior Consultant, Core Modalities Asia Pacific, Bioprocessing Strategy
Gene Xpert
This is a presentation giving an overview of the GeneXpert DX system for detection of MTB. The assay described in this presentation is the MTB/RIF test.
New Technology and Workflow for Integrated Collection, Stabilization and Puri...
Research into non-invasive prenatal testing (NIPT) and circulating tumor DNA (ctDNA) testing based on circulating cell-free DNA (ccfDNA) is rapidly expanding. However, detection and quantification of ccfDNA is compromised by the release of genomic DNA (gDNA) from lymphocytes due to mechanical lysis or apoptosis during blood collection, storage and transport. PreAnalytiX has developed the PAXgene® Blood ccfDNA System, consisting of the PAXgene Blood ccfDNA Tube, a plastic blood collection tube with a unique, non-crosslinking chemistry that preserves extracellular levels of ccfDNA and prevents the release of intracellular DNA from cells into the plasma, and the QIAsymphony® PAXgene Blood ccfDNA Kit for automated ccfDNA extraction from up to 5 ml of plasma. In this webinar, this new technology development is presented in comparison to other existing technologies.
Use of rapid quality control test methods as alternatives to traditional meth...
Abstract:
As the market for advanced therapy medicinal products (ATMP) matures the complexities of these molecules are evident and challenging when routine standard quality control (QC) testing is applied. Short shelf life from the point of manufacture to administration to the patient results in relatively low volumes for small scale clinical trials or small patient populations. Within a limited time period and with this low product volume, it is necessary to complete required regulatory QC testing, be that for early or late phase clinical trials, or for licensed drug product in a reduced timescale. So, the challenges with QC testing of cell and gene therapies using traditional test methods is time to results, due to short shelf-life, and availability of sufficient sample, due to low production volumes. Over the past years the application of rapid testing of short-life cell and gene therapies that may also help conserve limited product availability have been utilised. Regulatory expectations for using rapid test methods in place of classical or compendial test methods have been defined and this presentation will provide examples and data from our own experience of a range of alternate methods for application to ATMP products.
To assess the effect of formalin on genomic DNA and assay performance for som...
What is the impact of assay failure in your laboratory and how do you monitor for it?
Application of Companion Diagnostics - driving better treatment for cancer patients
AAV production protocol:packaging,concentration and purification-gene medi
AAV production protocol for AAV vector construction, AAV packaging and AAV purification.
Massively parallel sequencing in forensic genetics
"Massively parallel sequencing in forensic genetics
Dr. Walther Parson
assoc. Prof. Institute of Legal Medicine, Innsbruck, Austria
adj. Prof. Penn State University, PA, USA"
What's hot (18)
Promises and Challenges of Manufacturing and Testing Viral Producer Cell Lines
Promises and Challenges of Manufacturing and Testing Viral Producer Cell Lines
Does your cell line have a secret? Avoid surprises with characterization
Does your cell line have a secret? Avoid surprises with characterization
Rapid Methodologies for Biosafety Testing of Biologic Therapeutics
Rapid Methodologies for Biosafety Testing of Biologic Therapeutics
New technology and workflow for integrated collection, stabilization and puri...
New technology and workflow for integrated collection, stabilization and puri...
Viral Risk Mitigation Strategies: Key Considerations in the Prevention and De...
Viral Risk Mitigation Strategies: Key Considerations in the Prevention and De...
Addressing the Pre-PCR Analytical Variability of FFPE Samples
Addressing the Pre-PCR Analytical Variability of FFPE Samples
Platform Technologies to Accelerate Novel Vaccine Development and Manufacturing
Platform Technologies to Accelerate Novel Vaccine Development and Manufacturing
New Technology and Workflow for Integrated Collection, Stabilization and Puri...
New Technology and Workflow for Integrated Collection, Stabilization and Puri...
Use of rapid quality control test methods as alternatives to traditional meth...
Use of rapid quality control test methods as alternatives to traditional meth...
To assess the effect of formalin on genomic DNA and assay performance for som...
To assess the effect of formalin on genomic DNA and assay performance for som...
Neil leblanc f7 rapid methods call amsterdam may 2010
Neil leblanc f7 rapid methods call amsterdam may 2010
AAV production protocol:packaging,concentration and purification-gene medi
AAV production protocol:packaging,concentration and purification-gene medi
Massively parallel sequencing in forensic genetics
Massively parallel sequencing in forensic genetics
Similar to NAIMA method
Rapid and real-time diagnosis of Laem-Singh virus using a portable Real-Amp T...
The most prominent of growth-retarded in black tiger shrimp (Penaeus monodon) is associated with an infection of Laem-Singh virus (LSNV) that has been involved the reduction of annual production volume. To more accurately, rapidly and easily determine its effect on shrimp industries for further control disease, a portable Real-Amp Turbidimeter with real-time detection method was evaluated for LSNV detection.The device exploited the turbidity that produced by-product of magnesium pyrophosphate and displayed turbidity values in real-time on the provided software screen. The results of quantitative can be accomplished by reaction time measuring. The sensitivity of a turbidity detection was comparable to that of the nested RT-PCR, while it was 1000-time more sensitive than RT-PCR. With the use of a portable Real-Amp Turbidimeter. The application of RT-LAMP using a portable Real-Amp Turbidimeter offers a simple and rapid detection platform for LSNV detection in the field assessment. So, This 's awesome technic not only for detection of LSNV but also for many pathogen.
Sequence based Markers
Different generations of sequencing methods are useful to determine nucleotide bases
Two-Tailed PCR - New Ultrasensitive and Ultraspecific Technique for the Quant...
Mikael Kubista, Department of Biotechnology, CAS and TATAA Biocenter
We present a highly specific, sensitive and cost-effective system to quantify miRNA expression based on novel chemistry called Two-tailed RT-qPCR. It takes advantage of target-specific primers for reverse transcription composed of two hemiprobes complementary to two different parts of the targeted miRNA, connected by a hairpin structure. The introduction of a second probe ensures high sensitivity and enables discrimination of highly homologous miRNAs irrespectively of the position of the mismatched nucleotide. Two-tailed RT-qPCR has a dynamic range of 7 logs and a sensitivity sufficient to detect less than ten target miRNA molecules. The reverse transcription step can be multiplexed and it allows for rapid testing with a total analysis time of less than 2.5 hours.
SNP genotyping on qPCR platforms: Troubleshooting for amplification and clust...
SNP genotyping on qPCR platforms: Troubleshooting for amplification and clust...Integrated DNA Technologies
Single-nucleotide polymorphisms (SNPs) provide important information about the biology and evolution of different organisms. SNPs may also help predict an individual’s response to certain drugs, susceptibility to environmental factors, and risk of developing particular diseases providing valuable insight into pathophysiology of the human condition. As a result, SNPs with important functional roles often become subjects for high-throughput experiments.
In this webinar, Daniel Tsang provides an overview of genotyping using real-time PCR (qPCR) technology, including challenges and ways to overcome these challenges. He presents a novel qPCR-based genotyping solution, the rhAmp™ SNP Genotyping System, along with its advantages in genotyping, details on cluster separation, as well as solutions to improve the calling accuracy and confidence of making genotype calls. Assay Development in Digital PCR
This talk outlines the general steps for project management in rapid development (design to data in two weeks) of a novel digital PCR assay to validate and quantify low frequency variants discovered by sequencing (NGS) of a targeted comprehensive cancer gene panel by the Ion Torrent PGM on PDX models of metastatic colon cancer and spheroid (3-D) cell cultures.
Goal: If the potential driver mutation is validated, treat both (PDX model & cell culture) with small molecule drugs, investigate coincident response.
Principle, Procedure and applications of Digital PCR.pptx
Digital PCR (dPCR) is the new generation PCR that enables absolute quantification of target gene by separating reac¬tion mixture in several compartments. In this system, copies of target nucleic acid are distributed randomly from 0, 1 or many in the several small volume compartments. Amplification is occurred in the compartment and resulting absorbance is measured. Integrated fluidic circuits, chip based microchambers, and water in oil droplets are the methods are used for separation of reaction mixture in to several compartments. BioMark HD system (Fluidigm, USA) and QuantStudio3D system (Thermofisher Scientific, USA) uses integrated fluidic circuits harbor¬ing 10000 to 40000 microchambers and integrated chip containing 20000 microchambers, respectively. In droplet digital PCR System (Biorad, USA), reaction mixture is separated into 20,000 water in droplets. After cycles of reaction using any of the above technologies, fluorescence is detected with an imaging sys¬tem in the each compartment and copy numbers of the target is calculated with imaging software.
In droplets digital PCR, after amplification, droplets containing target gene are detected by fluorescence and scored as positive, and droplets without fluorescence are scored as negative. Poisson statistical analysis of the numbers of positive and negative droplets yields absolute quantitation of the target sequence. Digital PCR is the preferred technique for absolute quantification of target gene without need of standard curve and higher sensitivity and produces highly reproducible results, and also less susceptible to inhibitors than conventional RT-qPCR
Multiplex Assays for Studying Gene Regulation and Cell Function
Multiplex Assays for Studying Gene Regulation and Cell FunctionMiraiBio Group of Hitachi Solutions America, Ltd.
Please note: This presentation accompanies a recorded webinar at:
https://www1.gotomeeting.com/register/347794241
Biomarkers for studying gene regulation and cell function can be efficiently analyzed by multiplexed methods. Dr. Jim Lazar from OriGene Technologies will provide an overview of four different but related detection technologies that can be used to analyze genetic variants, microRNA expression, transcription factor binding, and protein expression on the Luminex xMAP platform. OriGene’s broad panel of assays and tools for discovery, analysis and validation of multiple classes of important biomarkers will allow researcher to develop more accurate descriptions of biologically complex systems.Massively Parallel Sequencing - integrating the Ion PGM™ sequencer into your ...
Massively Parallel Sequencing - integrating the Ion PGM™ sequencer into your ...Thermo Fisher Scientific
"Massively Parallel Sequencing - integrating the Ion PGM™ sequencer into your forensic laboratory.
Dr. SallyAnn Harbison
March 2015"Molecular diagnosis of Mycobacterium tuberculosis TB - Second MBBS -
MOLECULAR DIAGNOSIS of MYCOBACTERIUM TUBERCULOSIS TB PPT - SECOND MBBS STUDENTS - UNDERGRADUATE STUDENTS - MEDICAL COLLEGE - POWERPOINT
Fruit breedomics workshop wp6 from marker assisted breeding to genomics assis...
FruitBreedomics WP6 training session
Similar to NAIMA method (20)
Rapid and real-time diagnosis of Laem-Singh virus using a portable Real-Amp T...
Rapid and real-time diagnosis of Laem-Singh virus using a portable Real-Amp T...
Two-Tailed PCR - New Ultrasensitive and Ultraspecific Technique for the Quant...
Two-Tailed PCR - New Ultrasensitive and Ultraspecific Technique for the Quant...
SNP genotyping on qPCR platforms: Troubleshooting for amplification and clust...
SNP genotyping on qPCR platforms: Troubleshooting for amplification and clust...
Principle, Procedure and applications of Digital PCR.pptx
Principle, Procedure and applications of Digital PCR.pptx
Multiplex Assays for Studying Gene Regulation and Cell Function
Multiplex Assays for Studying Gene Regulation and Cell Function
Massively Parallel Sequencing - integrating the Ion PGM™ sequencer into your ...
Massively Parallel Sequencing - integrating the Ion PGM™ sequencer into your ...
Molecular diagnosis of Mycobacterium tuberculosis TB - Second MBBS -
Molecular diagnosis of Mycobacterium tuberculosis TB - Second MBBS -
Fruit breedomics workshop wp6 from marker assisted breeding to genomics assis...
Fruit breedomics workshop wp6 from marker assisted breeding to genomics assis...
NAIMA method
- 1. APPLICATION OF NAIMA-MA FOR FAST HIGH THROUGHPUT AND QUANTITATIVE GMO DETECTION Dany Morisset , David Dobnik, Tina Likar and Kristina Gruden Department of Biotechnology and Systems Biology National Institute of Biology Ljubljana, Slovenia [email_address]
- 3. WP5 & & meeting 11-12 May Ljubljana ssRNA/ss c DNA 100-1000 copies NASBA principle T7-RNA polymerase promoter sequence + specific sequence Second target specific sequence second specific primer Reverse Transcription RNAse H activit y T7-specific primer Primer extension Transcription 3’ 5’ RNA 3’ c DNA (-) Reverse Transcription 5’ 5’ ds cDNA 3’ RNA pol Primer extension 5’ 3’ 3’ 5’ ss DNA 5’ 5’ 3’ RNA (-) 3’ 3’ 3’ 3’ 3’ 3’ 3’ 3’ 3’
- 5. NAIMA multiplex template synthesis 5’ 3’ T7-RNA polymerase promoter sequence + universal sequence Second universal sequence Target specific sequence Denaturation, specific “tailed” primers Primer extension (no cycling) ds DNA Host DNA Host DNA Gene Term Prom 5’ 3’ 5’ 3’ 5’ 3’ 5’ 3’ 5’ 3’ 5’ 3’ 5’ 3’ 5’ 3’
- 6. WP5 & & meeting 11-12 May Ljubljana ssRNA/ssDNA RNA (-) 100-1000 copies NAIMA universal amplification ss DNA T7-RNA polymerase promoter sequence + universal sequence Second universal sequence second universal primer Reverse Transcription RNAse H activities T7-universal primer Primer extension 3’ 5’ Transcription 3’ 5’ 3’ 5’ 3’ 3’ 3’ 3’ 3’ 3’ 3’ RNA pol 5’ 3’ ds DNA 5’ 3’
Editor's Notes
- Say multiplex can be extended. Possibility of matrix-based detection for UGM
- Say multiplex can be extended. Possibility of matrix-based detection for UGM